secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001549595-23-000062
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix reports positive Phase 1 data for BTK degraders NX-5948 and NX-2127 at ASH 2023
--------------------------------------------------------------------------------

- NX-5948: 3 partial responses in CLL (n=7); no DLTs or treatment-related SAEs across 50-450 mg doses.
- NX-2127: 2 complete responses in NHL (MCL, DLBCL); 40.7% ORR in CLL (n=27), up from 33% at ASH 2022.
- NX-2127 safety manageable: neutropenia dose-related, atrial fibrillation 11.1% (down from 17% prior).
- Dose escalation continues for both programs; more data expected in 2024.
- Company plans to develop NX-5948 broadly in CLL and other NHL indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000062/0001549595-23-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000062/nrix-20231211.htm
  HTML page:      https://secwatch.observer/filing/0001549595-23-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer